Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||M6223 + M7824|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|M6223||M-6223|M 6223||M6223 targets and binds to TIGIT on immune cells, including tumor-infiltrating lymphocytes, and prevents its interaction with CD112 and CD155, thereby leading to enhanced interaction of CD112 and CD155 with CD226 expressed on natural killer and CD8 T+ cells, which may lead to the activation of anti-tumor immune responses (NCI Drug Dictionary).|
|M7824||Bintrafusp alfa|MSB0011359C||Immune Checkpoint Inhibitor 135 PD-L1/PD-1 antibody 79 TGFBR2 Antibody 2||Bintrafusp alfa (M7824) is a human PD-L1 (CD274) antibody fused with transforming growth factor-beta (TGF-beta, TGFBR2) receptor II extracellular domain, which blocks two immuno-inhibitory pathways simultaneously, therefore enhances anti-tumor immunity (PMID: 29298798, PMID: 32461347).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04457778||Phase I||M6223 M6223 + M7824||First in Human Study of M6223 in Participants With Metastatic or Locally Advanced Solid Unresectable Tumors||Recruiting||USA | CAN||0|